LISTING OF CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application. In the amended claims, additions are shown as underlined and deletions are shown as ~~struckthrough~~.

1. (Currently Amended) A controlled release system, comprising 4-10 wt% ~~3-10wt%~~ of temozolomide and biodegradable polyanhydrides, wherein the controlled release system releases temozolomide for a period ranging from 6 hours to 4 weeks *in vivo* ~~polymeric materials~~.

2. (Original) The controlled release system according to claim 1, which is implantable tablet.

3. (Canceled)

4. (Canceled)

5. (Currently Amended) The controlled release system according to claim 1 ~~claim 4~~, wherein the polyanhydrides are ~~said poly(anhydride) is one~~ condensed from 1,3-bis(p-carboxyphenoxy) propane ~~3,4-bis(p-carboxyphenoxy) propane~~ (CPP) and sebacic acid (SA).

6. (Canceled)

7. (Currently Amended) A process of preparing the temozolomide controlled release tablets, comprising:
   a. Dissolving the polyanhydrides ~~polymeric materials~~ in a solvent to give a solution of polyanhydrides ~~polymeric materials~~;

b. Dispersing temolozomide in or mixing temolozomide with the ~~said~~ solution of polyanhydrides ~~polymeric materials~~ to produce a mixture of polyanhydrides ~~polymeric materials~~ and temolozomide;

c. Spray-drying the ~~said~~ mixture of polyanhydrides ~~polymeric materials~~ and temolozomide to obtain microspheres; and

d. Tabletting the ~~said~~ microspheres to obtain implantable tablets;

wherein the controlled release system releases temozolomide for a period ranging from 6 hours to 4 weeks *in vivo*.

8. (Canceled)

9. (Canceled)

10. (Currently Amended) The process according to claim 7, wherein the ~~said~~ solvent in step (a) is methylene chloride.

11. (Currently Amended) A process of preparing the temozolomide controlled release tablets, comprising:

a. Dissolving the polyanhydrides ~~polymeric materials~~ in a solvent to give a solution of polyanhydrides ~~polymeric materials~~;

b. Adding temolozomide into the ~~said~~ solution of polyanhydrides ~~polymeric materials~~ and ultrasonic-emulsifying the resultant solution to obtain a first emulsion;

c. Mixing the ~~said~~ first emulsion with polyvinyl alcohol (PVA), followed by evaporating the solvent to obtain hard microspheres;

d. Eliminating PVA and residual solvent by washing with water to obtain microspheres; and

e. Tabletting the ~~said~~ microspheres to obtain implantable tablets;

wherein said controlled release system releases temozolomide for a period ranging from 6 hours to 4 weeks *in vivo*.

12. (Canceled)

13. (Canceled)

14. (Currently Amended) The process according to claim 11, wherein the ~~said~~ solvent in step (a) is methylene chloride.